Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

rF1V-1018

Phase 2Biologic

DDynavax Technologies Corporation

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

PlagueActive, not recruiting

PlaguePhase 2

Active, not recruiting

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Plague

NCT07207408

Clinical

Trials by Indication[1]

Immunogenicity1 trial

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Completed·DDynavax Technologies Corporation·Phase 2·NCT05506969·200 enrolled

Plague1 trial

Phase 2, Randomized, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

Active, not recruiting·DDynavax Technologies Corporation·Phase 2·NCT07207408·148 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for rF1V-1018. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rF1V-1018 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rF1V-1018. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dynavax Technologies Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: DDynavax Technologies Corporation

Related News